Spots Global Cancer Trial Database for cin2
Every month we try and update this database with for cin2 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age | NCT03177863 | CIN2 Therapy | Expectancy | 25 Years - 30 Years | Sahlgrenska University Hospital, Sweden | |
| Management of Cervical Intraepithelial Neoplasia Grade 2 | NCT00733109 | Cervical Intrae... | Excision of the... Follow-up for s... | 18 Years - 61 Years | Universidade Cidade de Sao Paulo | |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04425291 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 4-valent HPV Va... 9-valent HPV Va... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | NCT05371353 | HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3 | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | ||
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05584332 | Cervical Cancer Genital Wart CIN1 CIN2 CIN3 Vain I Vain III Vin I Vin II Vin III AIS VAIN - Vaginal ... | Quadrivalent Hu... Placebo | 18 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years | NCT04895020 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent HPV va... | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Cervical Cancer Screening With Human Papillomavirus Testing | NCT01881659 | CIN3 CIN2 Cervical Cancer | HPV screening | 30 Years - 64 Years | International Agency for Research on Cancer | |
| Regression of Cervical Precancerous Lesions and Associated Risk Factors | NCT06147388 | Cervix Uteri SI... HPV CIN2 CIN3 | Colposcopy | 18 Years - 40 Years | General University Hospital, Prague | |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | NCT05027776 | HPV Infections Cervical Cancer... Vaginal Cancer Genital Wart CIN1 CIN2 CIN3 | 2-doses Group a... 3-doses Group a... 3-doses Group a... | 9 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa | NCT05413798 | Cervical Cancer CIN2 CIN3 | Urine HPV testi... Self-collected ... Provider-collec... | 25 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT03676101 | Cervical Cancer... Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN 3 AIS Invasive Carcin... Mild Dysplasia ... Moderate Dyspla... Vin III VaIN1 VaIN2 VaIN3 Genital Wart | 9-valent HPV Re... Placebo | 9 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age | NCT03177863 | CIN2 Therapy | Expectancy | 25 Years - 30 Years | Sahlgrenska University Hospital, Sweden | |
| Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV | NCT05413811 | Cervical Cancer CIN2 CIN3 Human Immunodef... Human Papilloma... | 5 Fluorouracil ... Placebo | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT05372016 | HPV Infections Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | Experimental: E... Active Comparat... | 16 Years - 26 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | NCT04422366 | Cervical Cancer Vulvar Cancer Vaginal Cancer CIN1 CIN2 CIN3 VaIN1 VaIN2 VaIN3 Genital Wart VIN 1 VIN 2 VIN 3 AIS | 9-valent Human ... GARDASIL® | 20 Years - 45 Years | Shanghai Bovax Biotechnology Co., Ltd. | |
| Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women. | NCT02956031 | Cervical Cancer High Grade Sil CIN2 | Screening Colposcopy LLETZ | 25 Years - 75 Years | University of Pretoria |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
